For Immediate Release

Chicago, IL – March 1, 2013 – Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks Rank #5 List – Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): General Cable Corporation (BGC) and Ternium S.A. (TX). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: Acorda Therapeutics Inc (ACOR) and Amsurg Corp (AMSG).

To see the full Zacks #5 Rank List - Stocks to Sell Now visit: http://at.zacks.com/?id=92

Since inception in 1988, the S&P 500 has outperformed the Zacks Rank #5 List of Stocks to Sell Now by 80% annually (+2% vs. +10%). While the rest of Wall Street continued to tout stocks during the market declines of the last few years, Zacks told investors which stocks to sell or avoid.

Here is a synopsis of why BGC and TX have a Zacks Rank of 5 (Strong Sell) and should most likely be sold or avoided for the next one to three months. Note that a #5 Strong Sell rating is applied to 5% of all the stocks in the Zacks Rank universe:

General Cable Corporation (BGC) announced fourth-quarter profit of 28 cents per share on February 25 which came behind the Zacks Consensus Estimate by 1 cent. The diluted earnings per share also fell by 6.67% on a year-over-year basis. The Zacks Consensus Estimate for the current year slipped 20 cents per share to $2.81 in the last 30 days. Next year’s estimate also dipped 10 cents per share to $3.54 per share in that time span.

Ternium S.A. (TX) posted a fourth -quarter loss of $1.29 per share on February 20, which came in $1.72 cents wider than the average forecast. The Zacks Consensus Estimate for 2013 fell to a profit of $2.68 per share from $2.87 over the past month with 2 out of 7 covering analysts slashed forecasts. Next year’s forecasts slipped 13 cents to $2.97 per share in the same time span.

Here is a synopsis of why ACOR and AMSG have a Zacks Rank of 4 (Sell) and should also most likely be sold or avoided for the next one to three months. Note that a #4 Sell rating is applied to 15% of all the stocks ranked by Zacks;

Acorda Therapeutics Inc (ACOR) fourth -quarter profit of 9 cents per share, posted on February 14, and lagged analysts’ projections by nearly 50.0%. For 2012, the Zacks Consensus Estimate moved down 3 cents to 71 cents in the last 30 days as 3 out of the 8 covering analysts cut back on forecasts. The forecast for next year slid 5 cents to $1.10 per share in the same time span.

Amsurg Corp (AMSG) reported a fourth-quarter profit of 49 cents per share on February 25, that fell 3.92% short of the Zacks Consensus Estimate. The full-year average forecast is currently pegged at $2.19 per share, compared with the last 30 days projection of $2.24. Next year’s forecast dropped 12 cents per share in the same period.